- A preclinical study led by researchers at the Vall d’Hebron Institute of Oncology has discovered potential targeted therapy options for patients with pseudomyxoma peritonei.
- The study involved generating patient-derived mouse models with identified KRAS and BRAF druggable targets to guide the selection of molecular targeted therapies.
- The researchers found that treatment with the BRAF inhibitor encorafenib in these preclinical models significantly reduced tumor growth and prolonged survival in mice.
- This discovery represents a promising step towards personalized systemic targeted therapy for patients who may benefit from molecularly matched treatments.
- The next step involves validating these findings in other models to investigate the efficacy of KRAS inhibitors and continue advancing precision oncology for patients with pseudomyxoma peritonei.
Source link
Oncology, General Surgery